Oncternal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 04:31 pm EDT
Share
Oncternal Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 8.97 million compared to USD 11.74 million a year ago. Basic loss per share from continuing operations was USD 3 compared to USD 4.6 a year ago. Diluted loss per share from continuing operations was USD 3 compared to USD 4.6 a year ago.
For the six months, net loss was USD 20.45 million compared to USD 21.65 million a year ago. Basic loss per share from continuing operations was USD 7 compared to USD 8.8 a year ago. Diluted loss per share from continuing operations was USD 7 compared to USD 8.8 a year ago.
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâs product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.